论文部分内容阅读
近日,来自美国的科学家在著名国际期刊nature发表了一项最新研究成果,他们通过对进行了PI(3)Kα抑制剂BYL719治疗的肿瘤转移病人进行基因测序,发现PTEN在基因组中的变化会导致肿瘤细胞出现对BYL719的抵抗作用。这项研究为临床应用PI(3)Kα抑制剂治疗肿瘤提供了重要参考价值。大范围深度的肿瘤基因组测序已经发现肿瘤异质性特点,并为不同肿瘤细胞克隆的转移进化特性提供了重要见解。但在另一个层面上,肿瘤进化可能受到治疗方法的选择压力,类似于在感染性疾病方面发生的情况。研究人员对一名携带PIK3CA基因突变并发生肿瘤转移的乳腺癌病
Recently, scientists from the United States published a recent study in the journal Nature, a well-known international journal that performed gene sequencing on patients with tumor metastases treated with the PI (3) Kα inhibitor BYL719 and found that changes in PTEN in the genome led to Tumor cells appear to BYL719 resistance. This study provides an important reference for the clinical application of PI (3) Kα inhibitors in the treatment of tumors. A wide range of tumor genome sequencing has found tumor heterogeneity and provided important insights into the metastatic properties of different tumor cell clones. On the other hand, tumor evolution may be under pressure to choose treatments that are similar to what happens with infectious diseases. Researchers on a PIK3CA gene mutation and tumor metastasis of breast cancer